MBC

PANEL EVENT: Transforming Behavioral Health Systems Through Measurement-Based Care

Retrieved on: 
Tuesday, April 16, 2024
Mental Health, Technology, Hospitals, Other Technology, Practice Management, Other Health, Managed Care, Continuing, Health, Education, CareSource, MBC, Joint, NHS, VBC, Joint Commission, Organization

Greenspace Health is excited to announce a new educational webinar featuring esteemed behavioral health experts from the Joint Commission, CareSource and the UK’s national mental health service, NHS Talking Therapies.

Key Points: 
  • Greenspace Health is excited to announce a new educational webinar featuring esteemed behavioral health experts from the Joint Commission, CareSource and the UK’s national mental health service, NHS Talking Therapies.
  • The purpose of the session is to share the impact and value of Measurement Based Care (MBC) for large organizations and health systems, along with strategic guidance to inform any large-scale implementation.
  • The panel of behavioral health innovators will share their insights on MBC, its role in helping organizations meet national accreditation standards, and how to leverage outcome data and insights to succeed within value-based care (VBC) payment models.
  • Registration for ‘Transforming Behavioral Health Systems through Measurement-Based Care’ is now open at greenspacehealth.com .

Grant Thornton names 51 Vets as its new Purple Paladin

Retrieved on: 
Tuesday, April 16, 2024
Veterans, Finance, Accounting, Professional Services, Philanthropy, Training, Foundation, Other Philanthropy, Education, Defense, Dignity, Volunteering, Personality, Dog, Grant Thornton International, Sports equipment, Hope, Hospital, Spectrum, Museum, Soldier, Book, Down syndrome, Vet, Hunger, Intellectual, Navy, Literature, Prescription, Survivor, Culture, Box, Hair loss, Immunodeficiency, Purple, MBC, Homelessness, Student, COVID-19, Organization, Veteran, Woman, Refugee, Tourism

51 Vets joins 18 other 501(c)(3) nonprofits that Grant Thornton previously selected as Purple Paladins.

Key Points: 
  • 51 Vets joins 18 other 501(c)(3) nonprofits that Grant Thornton previously selected as Purple Paladins.
  • Grant Thornton’s Purple Paladins program derives its name from the word paladin, a champion of a cause.
  • Grant Thornton and its professionals have donated more than $1 million to Purple Paladin nonprofits, and more than 650 Grant Thornton professionals have volunteered their time and skills to support the firm’s Purple Paladins.
  • To learn more about Purple Paladins, or to nominate a nonprofit for potential support, visit Grant Thornton’s website: www.grantthornton.com/PurplePaladins .

Welligent and Greenspace Health Announce Strategic Integration

Retrieved on: 
Thursday, April 11, 2024
Data Management, Mental Health, Health, Technology, Other Technology, Software, MBC, Workflow, Evidence-based practice, EHR, Partnership, Organization, Risk management

Welligent , a part of the ContinuumCloud spectrum of solutions for social good, and Greenspace Health are pleased to announce that they have entered into a strategic partnership.

Key Points: 
  • Welligent , a part of the ContinuumCloud spectrum of solutions for social good, and Greenspace Health are pleased to announce that they have entered into a strategic partnership.
  • This strategic alliance will integrate Greenspace Health’s best-in-class Measurement-Based Care (MBC) platform into Welligent’s leading cloud-based EHR software for behavioral health providers.
  • The collaboration between Welligent and Greenspace Health will empower providers with a best-in-class MBC solution that is seamlessly integrated into their EHR system.
  • “This integration delivers clear insights into customers’ performance against treatment targets, and will empower care teams to make timely treatment adjustments that enhance their quality of care for all clients.”
    The integration is launching across select Greenspace and Welligent partners.

MasterBrand to Announce First Quarter 2024 Results on May 7

Retrieved on: 
Wednesday, April 10, 2024
Home Goods, Construction & Property, Other Manufacturing, Other Construction & Property, Interior Design, Manufacturing, Retail, Residential Building & Real Estate, MBC, Webcast

MasterBrand, Inc. (NYSE: MBC, the “Company,” or “MasterBrand”), the largest residential cabinet manufacturer in North America, today announced it will release its first quarter 2024 financial results after the market close on Tuesday, May 7, 2024.

Key Points: 
  • MasterBrand, Inc. (NYSE: MBC, the “Company,” or “MasterBrand”), the largest residential cabinet manufacturer in North America, today announced it will release its first quarter 2024 financial results after the market close on Tuesday, May 7, 2024.
  • ET the same day to discuss the financial results and business outlook.
  • The live audio webcast can be accessed on the “Investors” section of the MasterBrand website at www.masterbrand.com .
  • A telephone replay will be available approximately one hour following completion of the call through May 21, 2024.

Biotech Innovations Paving the Way in Breast Cancer Fight

Retrieved on: 
Thursday, April 11, 2024
AstraZeneca, Breast cancer, Gilead Sciences, FDA, Radiation, University, PARP1, Cancer, Bone marrow, G1 Therapeutics, Paclitaxel, Protein, GILD, Safety, PARP, Pancreatic cancer, News, Progression-free survival, Survival, Estate (law), American Cancer Society, TSX, OS, Fast track (FDA), MBC, ONC, PETRA, Data monitoring committee, Rated R, Patient, Sacituzumab govitecan, Hologic, HOLX, Neoplasm, Death, DMC, AACR, Immune system, Type, TNBC, Trilaciclib, Pharmaceutical industry

VANCOUVER, BC, April 11, 2024 /PRNewswire/ -- USA News Group – The American Cancer Society is projecting 2024 to be the first year ever for the US to have more than 2 million new cases, which would represent a record high. Among 10 of the most common cancers, 6 have seen a rise in diagnoses, including the most common type of cancer in women—breast cancer. According to the World Health Organization breast cancer caused 670,000 deaths globally in 2022, and is predicting a 77% increase in new cancer cases by 2050. Based on the characteristics of each patient's tumor, how each patient is treated may be completely different from others. Broadening our ability to tackle breast cancer are several biotech developments including from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Gilead Sciences, Inc. (NASDAQ:GILD), G1 Therapeutics, Inc. (NASDAQ:GTHX), AstraZeneca PLC (NASDAQ:AZN), and Hologic, Inc. (NASDAQ:HOLX).

Key Points: 
  • According to the World Health Organization breast cancer caused 670,000 deaths globally in 2022 , and is predicting a 77% increase in new cancer cases by 2050 .
  • Broadening our ability to tackle breast cancer are several biotech developments including from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Gilead Sciences, Inc. (NASDAQ:GILD), G1 Therapeutics, Inc. (NASDAQ:GTHX), AstraZeneca PLC (NASDAQ:AZN), and Hologic, Inc. (NASDAQ:HOLX).
  • Coming off of a late-2022 FDA Fast Track Designation of Oncolytics Biotech Inc.'s (NASDAQ:ONCY) (TSX:ONC) flagship asset pelareorep for the treatment of pancreatic cancer, momentum is building towards another important FDA milestone, this time for breast cancer.
  • "We are optimistic that pelareorep, in combination with paclitaxel, could significantly enhance clinical outcomes for patients with HR+/HER2- metastatic breast cancer.

Biotech Innovations Paving the Way in Breast Cancer Fight

Retrieved on: 
Thursday, April 11, 2024
AstraZeneca, Breast cancer, Gilead Sciences, FDA, Radiation, University, PARP1, Cancer, Bone marrow, G1 Therapeutics, Paclitaxel, Protein, GILD, Safety, PARP, Pancreatic cancer, News, Progression-free survival, Survival, Estate (law), American Cancer Society, TSX, OS, Fast track (FDA), MBC, ONC, PETRA, Data monitoring committee, Rated R, Patient, Sacituzumab govitecan, Hologic, HOLX, Neoplasm, Death, DMC, AACR, Immune system, Type, TNBC, Trilaciclib, Pharmaceutical industry

VANCOUVER, BC, April 11, 2024 /PRNewswire/ -- USA News Group – The American Cancer Society is projecting 2024 to be the first year ever for the US to have more than 2 million new cases, which would represent a record high. Among 10 of the most common cancers, 6 have seen a rise in diagnoses, including the most common type of cancer in women—breast cancer. According to the World Health Organization breast cancer caused 670,000 deaths globally in 2022, and is predicting a 77% increase in new cancer cases by 2050. Based on the characteristics of each patient's tumor, how each patient is treated may be completely different from others. Broadening our ability to tackle breast cancer are several biotech developments including from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Gilead Sciences, Inc. (NASDAQ:GILD), G1 Therapeutics, Inc. (NASDAQ:GTHX), AstraZeneca PLC (NASDAQ:AZN), and Hologic, Inc. (NASDAQ:HOLX).

Key Points: 
  • According to the World Health Organization breast cancer caused 670,000 deaths globally in 2022 , and is predicting a 77% increase in new cancer cases by 2050 .
  • Broadening our ability to tackle breast cancer are several biotech developments including from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Gilead Sciences, Inc. (NASDAQ:GILD), G1 Therapeutics, Inc. (NASDAQ:GTHX), AstraZeneca PLC (NASDAQ:AZN), and Hologic, Inc. (NASDAQ:HOLX).
  • Coming off of a late-2022 FDA Fast Track Designation of Oncolytics Biotech Inc.'s (NASDAQ:ONCY) (TSX:ONC) flagship asset pelareorep for the treatment of pancreatic cancer, momentum is building towards another important FDA milestone, this time for breast cancer.
  • "We are optimistic that pelareorep, in combination with paclitaxel, could significantly enhance clinical outcomes for patients with HR+/HER2- metastatic breast cancer.

Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA

Retrieved on: 
Thursday, April 11, 2024
FDA, CDK, Paclitaxel, Progression-free survival, Survival, TSX, AB, MBC, ONC, Patient, Biomarker, SAN, Type, Breast cancer, Overalls, Pharmaceutical industry

SAN DIEGO and CALGARY, AB, April 11, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapeutics for oncology, is pleased to announce the submission of a Type C meeting request to the FDA. This meeting aims to discuss the Company's planned registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer (mBC).

Key Points: 
  • This meeting aims to discuss the Company's planned registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer (mBC).
  • "A key focus for Oncolytics in 2024 is defining the regulatory path for pelareorep in breast cancer treatment.
  • We are optimistic that pelareorep, in combination with paclitaxel, could significantly enhance clinical outcomes for patients with HR+/HER2- metastatic breast cancer.
  • "We eagerly anticipate our discussion with the FDA to align on the design and objectives of the registrational trial for pelareorep in metastatic breast cancer, a critical step towards bringing this innovative treatment to patients.

Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA

Retrieved on: 
Thursday, April 11, 2024
FDA, CDK, Paclitaxel, Progression-free survival, Survival, TSX, AB, MBC, ONC, Patient, Biomarker, SAN, Type, Breast cancer, Overalls, Pharmaceutical industry

SAN DIEGO and CALGARY, AB, April 11, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapeutics for oncology, is pleased to announce the submission of a Type C meeting request to the FDA. This meeting aims to discuss the Company's planned registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer (mBC).

Key Points: 
  • This meeting aims to discuss the Company's planned registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer (mBC).
  • "A key focus for Oncolytics in 2024 is defining the regulatory path for pelareorep in breast cancer treatment.
  • We are optimistic that pelareorep, in combination with paclitaxel, could significantly enhance clinical outcomes for patients with HR+/HER2- metastatic breast cancer.
  • "We eagerly anticipate our discussion with the FDA to align on the design and objectives of the registrational trial for pelareorep in metastatic breast cancer, a critical step towards bringing this innovative treatment to patients.

Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates

Retrieved on: 
Tuesday, March 19, 2024
HER2, Acute leukemia, Exercise, Index, Exchange, Colorectal cancer, MMR, Memorial, Headache, Patient, Research, Diarrhea, Brain, CML, KOL, Aes, Sale, Cancer, Security (finance), IND, MBA, Prospectus, MBC, Nausea, Therapy, CRC, PIPE, Pharmacokinetics, MTD, Food, Pharmaceutical industry

BOULDER, Colo., March 19, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced that it has entered into a securities purchase agreement for a private investment in public equity (PIPE) financing that is expected to result in gross proceeds of approximately $90 million, before deducting offering expenses. The financing includes participation from new and existing investors, including Commodore Capital, Fairmount, Venrock Healthcare Capital Partners, a biotech investor, a large mutual fund, Rock Springs Capital, Logos Capital, Woodline Partners LP and Acuta Capital Partners.

Key Points: 
  • “The additional funding further strengthens our balance sheet and enables us to achieve critical, longer-term clinical milestones as we advance our parallel lead programs, ELVN-001 and ELVN-002.
  • Enliven anticipates the gross proceeds from the private placement to be approximately $90 million, before deducting offering expenses.
  • The PIPE financing is expected to close on or about March 21, 2024, subject to satisfaction of customary closing conditions.
  • Any offering of the securities under the resale registration statement will only be made by means of a prospectus.

Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

Retrieved on: 
Thursday, March 14, 2024
Research, U.S. FDA, Trastuzumab, Colorectal cancer, Patient, Food and Drug Administration, CML, Running, G&A, Disclosure, MBA, MBC, Therapy, Cancer, CRC, FDA, Food, Pharmaceutical industry

BOULDER, Colo., March 14, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today reported financial results for the fourth quarter and full year ended December 31, 2023, provided updated guidance on parallel lead product candidates and highlighted pipeline progress.

Key Points: 
  • Research and development (R&D) expenses: R&D expenses were $17.9 million for the fourth quarter of 2023, compared to $8.2 million for the fourth quarter of 2022.
  • General and administrative (G&A) expenses: G&A expenses for the fourth quarter of 2023 were $4.8 million, compared to $2.0 million for the fourth quarter of 2022.
  • Net Loss: Enliven reported a net loss of $19.4 million for the fourth quarter of 2023, compared to a net loss of $9.6 million for the fourth quarter of 2022.
  • Total net loss for the full year 2023 was $71.6 million, compared to $37.7 million for the full year 2022.